Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

about

Quantitative Framework for Retrospective Assessment of Interim Decisions in Clinical Trials.A decade of Clinical Trials.

P2860

Q41268199-FA90D2B1-929C-4FDE-8DCA-DB71195F5824 Q46750545-473B50A1-72A6-473C-BB87-0502BBD71DB4

P2860

Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

Item

http://www.wikidata.org/entity/Q51907394

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

@en

Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

@nl

type

Item

label

Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

@en

Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

@nl

prefLabel

Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

@en

Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

@nl

P1476

Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

@en

P2093

Steven N Goodman

http://www.w3.org/2001/XMLSchema#string

P2860

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

Issues in data monitoring and interim analysis of trials.

Where's the utility in Bayesian data-monitoring of clinical trials?

Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.

Behind closed doors: the data monitoring board in randomized clinical trials.

A decision-theoretic evaluation of early stopping rules.

Approached to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative.

The UGDP controversy. Clinical trials versus clinical impressions.

P304

205-206

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1177/1740774507079655

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17715245

http://www.w3.org/2001/XMLSchema#string

Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

about

P2860

P2860

Rashomon revisited: two views of monitoring the Women's Health Initiative trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698